{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-090878","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.043777+00:00","generated_at":"2026-06-11T11:53:00.211564+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acurx Pharma Q2 net loss widens to $3.4M; Phase 2b enrollment ongoing","bullets":["Net loss Q2 2023: $3.4M ($0.28/sh) vs $2.6M ($0.26/sh) in Q2 2022.","Cash unchanged at $9.1M as of June 30, 2023; no revenue reported.","Phase 2b trial for ibezapolstat in C. difficile: 28 sites enrolling; 5 patients needed for interim IDMC review.","R&D expenses rose to $1.7M (Q2 2023) from $0.9M (Q2 2022) driven by Phase 2b costs.","CARB-X declined grant for ACX375C pre-clinical candidate; encouraged re-application."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-090878","json":"https://secwatch.observer/filing/0001104659-23-090878.json","markdown":"https://secwatch.observer/filing/0001104659-23-090878.md","text":"https://secwatch.observer/filing/0001104659-23-090878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923090878/0001104659-23-090878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923090878/tm2323535d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:53:00.211564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a40c66c7ae559fa1fc9b2d8da5bfb90df54410b","claim":"Acurx Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $3.4 million or $0.28 per diluted share, EPS $0.28 per diluted share.","evidence_excerpt":"The Company reported a net loss of $3.4 million or $0.28 per diluted share for the three months ended June 30, 2023, compared to a net loss of $2.6 million or $0.26 per diluted share for the three months ended June 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923090878/0001104659-23-090878-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"a net loss of $3.4 million or $0.28 per diluted share"},{"label":"EPS","value":"$0.28 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}